{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:14:50Z","timestamp":1774584890532,"version":"3.50.1"},"reference-count":48,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,8]]},"abstract":"<jats:p>Preclinical evidence indicates that prion diseases can respond favorably to passive immunotherapy. However, certain antibodies to the cellular prion protein PrPC can be toxic. Comprehensive studies of structure\u2013function relationships have revealed that the flexible amino-terminal tail of PrPC is instrumental for mediating prion toxicity. In a first-in-human study, an anti-prion antibody has been recently administered to patients diagnosed with sporadic Creutzfeldt\u2013Jakob's disease, the most prevalent human prion disease. Moreover, large-scale serosurveys have mapped the prevalence of naturally occurring human anti-prion autoantibodies in health and disease. Here, we provide a perspective on the limitations and opportunities of therapeutic anti-prion antibodies.<\/jats:p>","DOI":"10.1042\/etls20200002","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T09:49:54Z","timestamp":1594115394000},"page":"169-173","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Recent developments in antibody therapeutics against prion disease"],"prefix":"10.1042","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-8857","authenticated-orcid":false,"given":"Karl","family":"Frontzek","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Aguzzi","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"2021111608142254500_ETLS-2020-0002CC1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nn.3120","article-title":"Prion propagation, toxicity and degradation","volume":"15","year":"2012","journal-title":"Nat. Neurosci."},{"key":"2021111608142254500_ETLS-2020-0002CC2","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1126\/science.1178250","article-title":"An analytical solution to the kinetics of breakable filament assembly","volume":"326","year":"2009","journal-title":"Science"},{"key":"2021111608142254500_ETLS-2020-0002CC3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/0092-8674(93)90360-3","article-title":"Mice devoid of PrP are resistant to scrapie","volume":"73","year":"1993","journal-title":"Cell"},{"key":"2021111608142254500_ETLS-2020-0002CC4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(20)30029-6","article-title":"New paradigms of clinical trial design for genetic prion diseases","volume":"19","year":"2020","journal-title":"Lancet Neurol."},{"key":"2021111608142254500_ETLS-2020-0002CC5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41576-018-0011-4","article-title":"Prions, prionoids and protein misfolding disorders","volume":"19","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"2021111608142254500_ETLS-2020-0002CC6","doi-asserted-by":"publisher","first-page":"6617","DOI":"10.1073\/pnas.85.18.6617","article-title":"Immunoaffinity purification and neutralization of scrapie prion infectivity","volume":"85","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111608142254500_ETLS-2020-0002CC7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1126\/science.1063093","article-title":"Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies","volume":"294","year":"2001","journal-title":"Science"},{"key":"2021111608142254500_ETLS-2020-0002CC8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nature01457","article-title":"Monoclonal antibodies inhibit prion replication and delay the development of prion disease","volume":"422","year":"2003","journal-title":"Nature"},{"key":"2021111608142254500_ETLS-2020-0002CC9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-pharmtox-010617-052745","article-title":"Toward therapy of human prion diseases","volume":"58","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2021111608142254500_ETLS-2020-0002CC10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12402","article-title":"The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein","volume":"501","year":"2013","journal-title":"Nature"},{"key":"2021111608142254500_ETLS-2020-0002CC11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0896-6273(00)00046-5","article-title":"Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice","volume":"27","year":"2000","journal-title":"Neuron"},{"key":"2021111608142254500_ETLS-2020-0002CC12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1471-4159.2004.02356.x","article-title":"Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation","volume":"89","year":"2004","journal-title":"J. Neurochem."},{"key":"2021111608142254500_ETLS-2020-0002CC13","doi-asserted-by":"publisher","first-page":"299ra123.","DOI":"10.1126\/scitranslmed.aab1923","article-title":"Structure-based drug design identifies polythiophenes as antiprion compounds","volume":"7","year":"2015","journal-title":"Sci. Trans. Med."},{"key":"2021111608142254500_ETLS-2020-0002CC14","doi-asserted-by":"publisher","first-page":"e1004662","DOI":"10.1371\/journal.ppat.1004662","article-title":"Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways","volume":"11","year":"2015","journal-title":"PLoS Pathog."},{"key":"2021111608142254500_ETLS-2020-0002CC15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-beta monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"2021111608142254500_ETLS-2020-0002CC16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson's disease: from genetics to the clinic","volume":"33","year":"2018","journal-title":"Mov. Disord."},{"key":"2021111608142254500_ETLS-2020-0002CC17","unstructured":"Sixth UCLH patient to receive innovative drug for CJD: UCLH; [Available from: https:\/\/www.uclh.nhs.uk\/News\/Pages\/SixthUCLHpatienttoreceiveinnovativedrugforCJD.aspx"},{"key":"2021111608142254500_ETLS-2020-0002CC18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1126\/science.1215579","article-title":"Prp antibodies do not trigger mouse hippocampal neuron apoptosis","volume":"335","year":"2012","journal-title":"Science"},{"key":"2021111608142254500_ETLS-2020-0002CC19","doi-asserted-by":"publisher","first-page":"e23473","DOI":"10.7554\/eLife.23473","article-title":"The N-terminus of the prion protein is a toxic effector regulated by the C-terminus","volume":"6","year":"2017","journal-title":"eLife"},{"key":"2021111608142254500_ETLS-2020-0002CC20","doi-asserted-by":"publisher","first-page":"e1005401","DOI":"10.1371\/journal.ppat.1005401","article-title":"Differential toxicity of antibodies to the prion protein","volume":"12","year":"2016","journal-title":"PLoS Pathog."},{"key":"2021111608142254500_ETLS-2020-0002CC21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","year":"2016","journal-title":"Nature"},{"key":"2021111608142254500_ETLS-2020-0002CC22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41582-019-0295-9","article-title":"Questions EMERGE as Biogen claims aducanumab turnaround","volume":"16","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"2021111608142254500_ETLS-2020-0002CC23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","year":"2014","journal-title":"Neuron"},{"key":"2021111608142254500_ETLS-2020-0002CC24","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3389\/fimmu.2017.01751","article-title":"Progress and challenges in the design and clinical development of antibodies for cancer therapy","volume":"8","year":"2017","journal-title":"Front. Immunol."},{"key":"2021111608142254500_ETLS-2020-0002CC25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1212\/WNL.57.5.801","article-title":"Reduced levels of amyloid beta-peptide antibody in Alzheimer disease","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"2021111608142254500_ETLS-2020-0002CC26","doi-asserted-by":"publisher","first-page":"eaah3924","DOI":"10.1126\/scitranslmed.aah3924","article-title":"A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis","volume":"10","year":"2018","journal-title":"Sci. Trans. Med."},{"key":"2021111608142254500_ETLS-2020-0002CC27","doi-asserted-by":"publisher","first-page":"12858","DOI":"10.1074\/jbc.M111.255836","article-title":"Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity","volume":"287","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021111608142254500_ETLS-2020-0002CC28","doi-asserted-by":"publisher","first-page":"e0163601","DOI":"10.1371\/journal.pone.0163601","article-title":"Neurotoxic antibodies against the prion protein do not trigger prion replication","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"2021111608142254500_ETLS-2020-0002CC29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nrneurol.2012.99","article-title":"Neuronal autoantigens\u2013pathogenesis, associated disorders and antibody testing","volume":"8","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"2021111608142254500_ETLS-2020-0002CC30","doi-asserted-by":"publisher","volume-title":"bioRxiv","year":"2020","DOI":"10.1101\/2020.02.05.933721"},{"key":"2021111608142254500_ETLS-2020-0002CC31","doi-asserted-by":"publisher","first-page":"a033134","DOI":"10.1101\/cshperspect.a033134","article-title":"Genetic PrP prion diseases","volume":"10","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2021111608142254500_ETLS-2020-0002CC32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009183","article-title":"Autoantibodies against the prion protein in individuals with PRNP mutations","year":"2020","journal-title":"Neurology"},{"key":"2021111608142254500_ETLS-2020-0002CC33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0002-9440(10)64151-X","article-title":"Immunization delays the onset of prion disease in mice","volume":"161","year":"2002","journal-title":"Am. J. Pathol."},{"key":"2021111608142254500_ETLS-2020-0002CC34","doi-asserted-by":"publisher","first-page":"e59143","DOI":"10.1371\/journal.pone.0059143","article-title":"Immunization with recombinant prion protein leads to partial protection in a murine model of TSEs through a novel mechanism","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"2021111608142254500_ETLS-2020-0002CC35","doi-asserted-by":"publisher","first-page":"206ra138","DOI":"10.1126\/scitranslmed.3006767","article-title":"Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice","volume":"5","year":"2013","journal-title":"Sci. Trans. Med."},{"key":"2021111608142254500_ETLS-2020-0002CC36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/37789","article-title":"A crucial role for B cells in neuroinvasive scrapie","volume":"390","year":"1997","journal-title":"Nature"},{"key":"2021111608142254500_ETLS-2020-0002CC37","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1126\/science.288.5469.1257","article-title":"Impaired prion replication in spleens of mice lacking functional follicular dendritic cells","volume":"288","year":"2000","journal-title":"Science"},{"key":"2021111608142254500_ETLS-2020-0002CC38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt\u2013Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","year":"2014","journal-title":"Lancet Neurol."},{"key":"2021111608142254500_ETLS-2020-0002CC39","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","article-title":"Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study","volume":"62","year":"2004","journal-title":"Neurology"},{"key":"2021111608142254500_ETLS-2020-0002CC40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","article-title":"Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial","volume":"8","year":"2009","journal-title":"Lancet Neurol."},{"key":"2021111608142254500_ETLS-2020-0002CC41","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1002\/j.1460-2075.1996.tb01027.x","article-title":"Chemical chaperones interfere with the formation of scrapie prion protein","volume":"15","year":"1996","journal-title":"EMBO J."},{"key":"2021111608142254500_ETLS-2020-0002CC42","doi-asserted-by":"publisher","first-page":"e131175","DOI":"10.1172\/jci.insight.131175","article-title":"Antisense oligonucleotides extend survival of prion-infected mice","volume":"4","year":"2019","journal-title":"JCI Insight"},{"key":"2021111608142254500_ETLS-2020-0002CC43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1471-4159.2009.05906.x","article-title":"Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy","volume":"109","year":"2009","journal-title":"J. Neurochem."},{"key":"2021111608142254500_ETLS-2020-0002CC44","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1073\/pnas.1303510110","article-title":"Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents","volume":"110","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111608142254500_ETLS-2020-0002CC45","doi-asserted-by":"publisher","first-page":"12396","DOI":"10.1523\/JNEUROSCI.6189-11.2012","article-title":"Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann\u2013Straussler\u2013Scheinker disease","volume":"32","year":"2012","journal-title":"J. Neurosci."},{"key":"2021111608142254500_ETLS-2020-0002CC46","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1474-4422(19)30403-X","article-title":"Towards a treatment for genetic prion disease: trials and biomarkers","volume":"19","year":"2020","journal-title":"Lancet Neurol."},{"key":"2021111608142254500_ETLS-2020-0002CC47","doi-asserted-by":"publisher","first-page":"e1007335","DOI":"10.1371\/journal.ppat.1007335","article-title":"A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity","volume":"14","year":"2018","journal-title":"PLoS Pathog."},{"key":"2021111608142254500_ETLS-2020-0002CC48","doi-asserted-by":"publisher","first-page":"104619","DOI":"10.1016\/j.nbd.2019.104619","article-title":"Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders","volume":"134","year":"2020","journal-title":"Neurobiol. Dis."}],"container-title":["Emerging Topics in Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/emergtoplifesci\/article-pdf\/4\/2\/169\/892632\/etls-2020-0002c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/emergtoplifesci\/article-pdf\/4\/2\/169\/892632\/etls-2020-0002c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T08:14:32Z","timestamp":1637050472000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/emergtoplifesci\/article\/4\/2\/169\/225714\/Recent-developments-in-antibody-therapeutics"}},"subtitle":[],"editor":[{"given":"Richard","family":"Reece","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,7]]},"published-print":{"date-parts":[[2020,9,8]]}},"URL":"https:\/\/doi.org\/10.1042\/etls20200002","relation":{},"ISSN":["2397-8554","2397-8562"],"issn-type":[{"value":"2397-8554","type":"print"},{"value":"2397-8562","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}